respiratory issues; the patient had received two total doses of Arexvy; This non-serious case was reported by a pharmacist via sales rep and described the occurrence of respiratory disorder in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included RSVPreF3 adjuvanted (Arexvy) for prophylaxis. Previously administered products included Shingrix (received 1st dose of Shingrix vaccine on unknown date) and Arexvy (received 1st dose of Arexvy vaccine in 2023). On an unknown date, the patient received the 2nd dose of Shingrix and the 2nd dose of Arexvy. On an unknown date, an unknown time after receiving Shingrix and Arexvy, the patient experienced respiratory disorder (Verbatim: respiratory issues) and extra dose administered (Verbatim: the patient had received two total doses of Arexvy). The outcome of the respiratory disorder and extra dose administered were unknown. It was unknown if the reporter considered the respiratory disorder to be related to Shingrix and Arexvy. It was unknown if the company considered the respiratory disorder to be related to Shingrix and Arexvy. Additional Information: GSK Receipt Date: 15-JAN-2025 Pharmacist reported that the patient was vaccinated with Shingrix at the same time as receiving her second dose of Arexvy which led to extra dose administered. After vaccination the patient had respiratory issues and was transported to the emergency department by personnel was made aware of the the vaccinations administered to the patient, however, was not informed the patient had received two total doses of Arexvy. No further information was known such as medical history of patient, demographics of patient, dates of administration for both doses of Arexvy and the dose of Shingrix, or the patient was admitted into the hospital or released from the emergency department. This case was linked with case US2025005052, reported by the same reporter for different patient.; Sender’s Comments: US-GSK-US2025005052:Same reporter/Different Patient